Allelic deletions of chromosome 18q are reported to be common in prostate and colorectal cancers, suggesting that one or more tumor suppressor genes on 18q are involved in the genesis of these neoplasms. The DPC4 gene, a recently identi®ed candidate tumor suppressor in 18q21, was examined for evidence of inactivation in prostatic carcinomas, and results compared to those of a parallel analysis of colorectal carcinomas, for which DPC4 mutation has been reported in *10% of cases. In this study, only three (10%) of 29 informative primary prostate cancers showed allelic loss of chromosome 18q21 markers, and no point mutations or deletions of DPC4 were detected in the complete set of 45 primary or metastatic cases. In contrast, ®ve (56%) of nine primary colorectal tumors displayed allelic loss of 18q markers and in one of these a somatically acquired G?T missense mutation was found in exon 1. Of twelve colorectal tumor cell lines, one showed a G?C missense mutation in exon 8 and two had partial homozygous deletions that would likely abrogate gene function. These data suggest that DPC4 is rarely if ever mutated during prostatic oncogenesis, whereas inactivation of this gene may contribute to the genesis of a subset of colorectal carcinomas.
Keywords: tumor suppressor gene; DPC4; mutation; prostate cancer; colorectal cancer Allelotyping and other molecular genetic studies in prostate cancer have identi®ed several genomic regions which may contain tumor suppressor genes (TSGs) (Carter et al., 1990; Kunimi et al., 1991; Visakorpi et al., 1995; Joos et al., 1995; Cunningham et al., 1996) . Chromosome arm 18q in particular is reported to suer loss of heterozygosity (LOH) in 17 ± 45% of prostate cancers (Carter et al., 1990; Kunimi et al., 1991; Gao et al., 1993; Latil et al., 1994; Brewster et al., 1994; Cunningham et al., 1996) . A candidate tumor suppressor gene at subband 18q21.1, deleted in colorectal carcinoma (DCC), was shown to have decreased or loss of expression in the majority of prostate cancers, and reduced expression was often associated LOH at the DCC locus (Gao et al., 1993) . However, examination of DCC for gene-speci®c inactivating mutations (point mutations, intragenic deletions) has been dicult due to the size and complexity of the gene, and to date the mutational status of DCC in prostate cancer is unclear. Another candidate gene at 18q21.1, deleted in pancreatic carcinoma 4 (DPC4), was isolated through positional cloning within homozygous deletions in pancreatic cancer . Homology searches in protein databases revealed that DPC4 is one of at least ®ve members of a family of genes (Smad1-5) which are involved in signal transduction of serine/threonine kinase receptors (Zhang et al., 1996; Derynk et al., 1996; Massague, 1996) . As the prototypic activator of such pathways, transforming growth factor-beta (TGFb) has been studied as a major growth inhibitory regulator of epithelial cells including prostatic epithelium (Fynan and Reiss, 1993) ; indeed, DPC4 has been implicated as a mediator of TGFb eects (Zhang et al., 1996; Lagna et al., 1996) . Many tumor cell lines show resistance to inhibition of cell growth by TGFb; for example, it has been shown that the growth rate of DU145 prostate tumor cells in culture is unaected (Zentella et al,. 1991) or only transiently impaired (Wilding et al., 1989) by TGFb treatment despite the presence of functioning TGFb receptors. It has been hypothesised that the insensitivity of epithelial tumor cells to external growth inhibitory signals elicited by TGFb may be due in part to the functional inactivation of intracellular eectors such as DPC4.
To determine whether DPC4 was involved in prostatic tumorigenesis, a panel of 45 prostate cancer specimens (32 primary tumors, Gleason grades 5 ± 7: 29 stage B/C, three stage D1; and 13 metastatic tumors) and four cell lines (TSU-Pr1, PPC-1, DU145, LNCaP) was surveyed for evidence of LOH, point mutations and genomic rearrangements or deletions. To validate the sensitivity of our screening methods, we analysed in parallel a set of 10 primary colorectal tumors (eight Duke's stage B/C, two stage D) and 12 cell lines (SW48, DLD-1, EB, SK-CO-1, HCT116, CACO-2, SW403, COLO320, COLO205, LS174T, HT-29 and RKO), some of which should harbour mutations of DPC4 (Thiagalingam et al., 1996) .
Twenty-nine primary prostate tumors and nine colorectal tumors for which paired normal tissue was available were informative for at least one of ®ve chromosome 18q21-speci®c markers, D18S57, D18S454, D18S474, D18S851, or D8S69 ( Figure 1 ). Allelic imbalance (AI) of at least one informative marker was observed in three of 29 primary prostatic cases. Imbalance of 18q21 markers was interpreted as allelic loss based on Southern blotting or comparative genomic hybridisation (CGH) data which suggested genetic loss rather than gain at 18q in prostate cancers (Carter et al., 1990; Kunimi et al., 1991; Latil et al., 1994; Brewster et al., 1994; Visakorpi et al., 1995; Joos et al., 1995; Cher et al., 1996) . In two cases, imbalance was observed at all informative loci; one tumor (#12) displayed a pattern consistent with allelic loss of D18S851 and retention of alleles at D18S454 ( Figure  1 ). AI was detected at all informative loci in 5 (56%) of nine primary colorectal cases, con®rming that chromosome 18q21 is frequently lost in colorectal cancers (Vogelstein et al., 1989; Cho et al., 1994) .
DPC4 is inactivated by homozygous deletion in over 30% of pancreatic cancers . In primary tumors, Southern analysis may fail to detect homozygous deletions due to the presence of contaminating benign cells in tumor tissue. We sought to avoid this problem by selecting primary tumors with 475% neoplastic cell content as determined by microscopic examination of hematoxylin/eosin-stained cryosections. This degree of purity was sucient for detection of allelic deletions of chromosome 8p markers by PCR, Southern blot or CGH analysis in 13 of 29 tumors Cher et al., 1994) . Nevertheless, Southern blots of DNA from 37 primary prostate tumors and four cell lines hybridised with a radiolabeled cDNA probe representing 495% of the coding sequence of DPC4 did not reveal any gross deletions or rearrangements (Figure 2 ). In contrast, examination of colorectal cancers, including 3 primary cases and 12 cell lines, revealed missing bands in COLO205 and SW403 suggestive of partial homozygous deletions ( Figure  2 ). In normal colonic mucosa, the 11 exons of DPC4 were ampli®ed in vitro by PCR in ten segments ranging from 224 bp to 556 bp (Figure 3a) . In COLO205, multiplex PCR of exons 1 through 7 using exon 8 as an internal control failed to amplify exons 1, 2, 3 and 4, suggesting that homozygous deletion involving these sequences had occurred (Figure 3b, top panel) . Likewise in SW403, multiplex analysis of exons 5 through 11 with exon 1 as control did not show ampli®cation of exons 10 and 11, although products for exons 5 to 9 could be generated under identical conditions (Figure 3b, bottom panel) .
To identify subtle genetic alterations such as point mutations in the full set of tumor DNAs, the 11 exons of DPC4 were ampli®ed in vitro and heat-denatured PCR products were screened for altered migration in nondenaturing gels (Orita et al., 1989) . Distinct electrophoretic mobilities associated with single-base substitutions were obtained in several instances ( Figure  4) . The variation displayed in one prostate tumor case (#87) was also found in paired normal DNA, suggesting that the change was constitutional ( Figure  4a ). Sequence analysis of tumor and normal DNA from this case revealed a sequence change (C to T) within intron 10, located 113 bp 5' of the splice acceptor site. This variant was considered to be an infrequent polymorphism. In one primary colon tumor (#3205, Figure 4b ), aberrant bands were associated with a missense mutation at codon 64 (GGA to GTA) producing a non-conservative substitution (glycine to valine). This tumor was found to have allelic loss at (Sambrook et al., 1989) . Reactions were performed in 10 ml volumes containing 50 ± 100 ng of template DNA, 50 ng of each primer, and other constituents as described previously Figure 2 Southern blot analysis. High molecular weight genomic DNA was prepared using standard methods (Sambrook et al., 1989) . Approximately 7 mg of genomic DNA were digested with excess HindIII restriction enzyme, fractionated on 1% agarose gels, and transferred to nylon membranes (Amersham). Filters containing HindIII-digested DNA from prostate (PPC-1, LNCaP, metastatic samples mPC3?11) and colorectal (CACO-2, COLO205, SW403) carcinoma cases were hybridised to a partial DPC4 cDNA fragment (bp 1 to 1620 of Genbank sequence U44378) radio-labeled with [a 32 P]dCTP by the random priming method, in RapidHyb solution (Amersham) for 1 ± 2 h. Final washes were in 0.16SSC, 0.5% SDS for 688C. Filters were exposed to phosphor-imager screens overnight. Band sizes (in kilobases) are indicated (right). Missing bands and an aberrant size fragment are indicated respectively by`*' and`~' DPC4 mutation in prostate cancer D MacGrogan et al 18q21 suggesting that bi-allelic mutation had occurred; residual normally-migrating bands may be derived from nonneoplastic cells in the tumor sample. The colorectal cell line CACO-2 exhibited a mobility shift of PCR products generated with primers speci®c for exon 8 (Figure 4c) . A GAT?CAT missense mutation was found at codon 351 leading to the substitution of asparagine with histidine. This mutation is identical to that of an ovarian tumor cell line , suggesting that the mutation is biologically relevant. Furthermore, CACO-2 was homozygous for all ®ve 18q21 microsatellite polymorphisms, suggesting loss of heterozygosity at the DPC4 locus. An additional mobility change in exon 7-speci®c products (not shown) was associated with two single base pair substitutions, C to G and C to T, located 5 and 57 bp 3' of the splice donor site. These alterations may represent so-called`passenger' mutations (Thiagalingam et al., 1996) . In the present study of colorectal cancers, only one of ®ve primary tumors with chromosome 18q LOH had a mutated DPC4 gene. Indeed, mutations of Smad2 (JV18-1/MADR2), another Smad family member located close to DPC4 in 18q21, have been found in a subset of colorectal tumors with allelic loss of 18q21 markers (Thiagalingam et al., 1996; Riggins et al., 1996; Eppert et al., 1996) . Of the 12 cultured colorectal tumor cell lines examined here, three exhibited altered DPC4 gene sequences. Taken together with the reported lack of DPC4 expression in SW480 cells (Zhang et al, 1996) , this gene is apparently abnormal in four (*30%) of 13 established colorectal cell lines. Although a comparison of mutation rates in primary tumors vs cell lines might suggest an association of DPC4 mutation with progression, a bias introduced by cell culture cannot be ruled out. Previous studies have shown that DPC4 missense mutations typically involve exons 2, 8 and 11 (Thiagalingam et al, 1996; Schutte et al, 1996; Nagatake et al., 1996; Kim et al., 1996) , the sequences of which are highly conserved between Smad genes in vertebrates and related genes in C. elegans and D. melanogaster (Derynk et al, 1996; Massague et al., 1996) . The genetic alterations identi®ed here (especially those of exons 8 and 10 ± 11) further support the existence of important functional domains in the DPC4 gene product.
Allelic loss at 18q21.1 in this set of paired tumor/ normal prostate tissues was uncommon (10%), although only primary cases were studied suciently. Single-strand conformation polymorphism (SSCP) analysis. DPC4 exons 1 through 11 were ampli®ed as in Figure  3 , except that [a
33
P]dATP was included in the reaction mixture. PCR products were digested with the following endonucleases (New England Biolabs) to obtain fragments of 100 ± 300 bp suitable for SSCP analysis: DraI or SacI (exon 1); SspI (exon 2); PstI (exons 3 and 10); MseI (exon 4); AccI or EaeI (exons 5 ± 6); ScaI (exon 11). After boiling for 2 min in the presence of 50% formamide, samples were loaded on gels containing 5% polycrylamide in 16TBE or 16MDE gel mix (FMC, Rockland, ME) in 0.66TBE. Gels were run at 40 W for 4 ± 5 h at room temperature or at 48C (polyacrylamide) or at 7 W for 14 h per manufacturer's instructions (MDE). Aberrant bands (arrows) were observed by autoradiography as follows: (a) exon 11/ScaI, MDE gel electrophoresis. (b) exon 1/Dra I, PAGE, 48C. (c) exon 8, PAGE, 48C. PCR products showing abnormal SSCP migration were separated by 1% preparative PAGE, puri®ed on silica matrices (Geneclean kit, Bio101), and cloned into pCRII cloning vector (Invitrogen). Transformants were plated on Amp LB-agar plates with X-gal for blue-white selection. White colonies were picked and grown for mini-scale plasmid preparation (Wizard Plus, Promega). Alternatively, abnormal bands were cut out of dried gels, eluted in water and reampli®ed as in Bookstein et al. (1993) Figure 3 Polymerase chain reaction analysis. DPC4 exons 1 through 11 (E1-E11) were ampli®ed in vitro in 10 segments of 4556 bp using primers within introns (sequences kindly provided by S Kern, Johns Hopkins University). PCR constituents and conditions were as in Figure 1 . PCR products were separated by 1.5% agarose gels and visualised by ethidium bromide staining. The discrepancy with previous reports of moderate to high levels of allelic loss at 18q21 may be attributed to dierences in tumor stage or grade. It has been suggested that chromosome 18q21 LOH is associated with advanced disease; of 6/23 (26%) cancers with allelic loss of the DCC locus, ®ve were of advanced stage and one was clinically localised (Brewster et al, 1994) . However, another study showing six (33%) of 18 informative stage B cases with allelic loss at DCC suggests otherwise (Latil et al., 1994) . Other factors which may explain con¯icting data between LOH studies include dierences in analytical techniques and origin and processing of tumor samples. In this respect, the materials and methods used in the present report most closely resemble those employed in a recent allelotype study (Cunningham et al, 1996) ; the tumors examined originated from the same patient population, and analytical methods were similar. Even so, the AI rate detected here at D18S851 diered signi®cantly from that reported in the latter study (12% vs 37%), although rates at nearby distal loci (D18S69 and DCC) were similar in both studies (*10%). The reason for this discrepancy is unclear at present.
Based on a low rate of 18q21 LOH in our primary prostate tumors, DPC4 mutations were anticipated to be rather infrequent in this cancer. Indeed, despite the use of two parallel methods that surveyed the entire gene, no abnormalities were detected in either early or advanced stage cases. The sensitivity of our methods was validated by successful detection of DPC4 mutations in colorectal tumors and cell lines at frequencies consistent with previous reports. In summary, our data suggest that mutational inactivation of DPC4 is uncommon during prostatic oncogenesis. Whether other genes involved in TGFb-family signaling pathways play a role in prostatic oncogenesis remains to be determined.
